BioSpace News Archive

The market will accelerate at a CAGR of over 4% between 2019-2023

Globe Life Inc. will release Third Quarter 2019 earnings after the market closes on Wednesday, Oct. 23 2019.

The market will accelerate at a CAGR of over 5% between 2019-2023

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO® and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease caused by Zaire Ebola virus.

Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90% lesion clearance rates over the course of therapy compared to vehicle

United Health Products, Inc. announced that it has received the final report from an independent review of the results of its human clinical trial.

Cipher Pharmaceuticals Inc. announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®, a Guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.

DEKRA Organizational Safety and Reliability, a global leader in safety at work, has announced a permanent and ongoing collaboration with Behavioral Safety Now for the 2020 Safety In Action Conference.

Centene Corporation and WellCare Health Plans, Inc. announced that the insurance departments of Arizona, Connecticut, Georgia, Ohio and Texas have now also approved Centene’s pending acquisition of WellCare, bringing the total number of states to approve the transaction to 24..

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.